December 27, 2016
1 min read
Save

Foundation makes two appointments

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The Reagan-Udall Foundation for the Food and Drug Administration, a nonprofit organization that strives to advance regulatory science to support the FDA’s scientific mission, elected two leaders of its board of directors.

Ellen V. Sigal, PhD, has been named board chairwoman. She served as acting board chair for the foundation since 2015.

Sigal is chair and founder of Friends of Cancer Research, a cancer research and advocacy organization based in Washington. She has served on the board of governors of the Patient Centered Outcomes Research Institute, the board of the Foundation for the National Institutes of Health, and the cancer moonshot blue ribbon panel.

“The Reagan-Udall Foundation is uniquely positioned to strengthen the FDA’s essential role in supporting innovation and advancing public health,” Sigal said in a press release. “I am honored to have been selected as chair of this exceptional organization. There are many important projects underway at the foundation that are enhancing the mission of the FDA, and many exciting opportunities on the horizon to advance regulatory science in a meaningful way and ultimately improve the lives of patients.”

Richard L. Schilsky, MD
Richard L. Schilsky

Richard L. Schilsky, MD, has been named the board’s vice chair.

Schilsky, a clinical oncologist and researcher, is senior vice president and chief medical officer of ASCO. He has held various leadership roles with ASCO, including serving as president. He also held several appointments at University of Chicago, where he served as director of the comprehensive cancer center, chief of the division of hematology–oncology and associate dean for clinical research.

“The Reagan-Udall Foundation has become an important mechanism for engaging a wide range of key stakeholders who are interested in supporting the FDA’s critical mission and advancing regulatory science,” Schilsky said in the release. “I am honored to have been selected to serve the foundation in this capacity.”